Sona Nanotech, Inc. · CSE:SONA

Sona Nanotech — Investor Presentation (November 2020)

20 slides from Sona Nanotech's investor presentation, November 2020

  1. Slide 1: Applying Gold Nanorod Technology to Disrupt Global Rapid Diagnostics Markets

    Slide 1: Applying Gold Nanorod Technology to Disrupt Global Rapid Diagnostics Markets

    APPLYING GOLD NANOROD TECHNOLOGY TO DISRUPT GLOBAL RAPID DIAGNOSTICS MARKETS WWW.SONANANO.COM CSE:SONA | OTC:SNANF

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS This presentation contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and

  3. Slide 3: Sona at a Glance

    Slide 3: Sona at a Glance

    SONA AT A GLANCE Sona Nanotech is a nanotechnology life sciences company that has developed multiple proprietary methods for the manufacture of gold nanorods (GNR’s). Nanotechnology: the use of matter on an atomic, molecular, and supramolecular scale Gold Nanorods: gold nanoparticles that are elonga

  4. Slide 4: The Global Rapid Diagnostic Market

    Slide 4: The Global Rapid Diagnostic Market

    THE GLOBAL RAPID DIAGNOSTIC MARKET Rapid Diagnostic Tests (RDT’s) are medical screening or diagnostic tests that are 2027 mobile, quick and easy to perform, and provide rapid results. $55.35B The global rapid test market is expected to grow to $55.35 Billion USD with 9.6% CAGR 2019 over the next six

  5. Slide 5: Sona's GNR Technology in LFA's

    Slide 5: Sona's GNR Technology in LFA's

    SONA’S GNR TECHNOLOGY IN LFA’S Lateral Flow Immunoassay (LFA’s) are simple, fast, and low-cost PoC diagnostic or screening tools which can provide rapid results (i.e. at-home pregnancy tests). Sona applies its proprietary GNR technology without CTAB in LFA’s to increase sensitivity while eliminating

  6. Slide 6: First Commercialization: COVID-19 Test

    Slide 6: First Commercialization: COVID-19 Test

    FIRST COMMERCIALIZATION: COVID-19 TEST Sona quickly recognized the opportunity to commercialize its GNR technology within an LFA test device to develop a rapid COVID-19 antigen test. EARLY DETECTION In-lab, sensitivity of 96% and specificity of 96%* and in-field of 94% and 94%, respectively, for pat

  7. Slide 7: History & Status of Sona's COVID-19 Rapid Antigen Test

    Slide 7: History & Status of Sona's COVID-19 Rapid Antigen Test

    HISTORY & STATUS OF SONA’S COVID-19 RAPID ANTIGEN TEST Q1 2020 Q2 2020 Q3 2020 Q4 2020 Achieved active In-field trials yield test COVID-19 project conjugate; positive test sensitivity of 85% and commences to COVID-19 viral antigens specificity of 90% PROOF OF AWAITING FEASIBILITY DEVELOPMENT OPTIMIZ

  8. Slide 8: The Importance of Frequent Rapid Antigen Test Screening

    Slide 8: The Importance of Frequent Rapid Antigen Test Screening

    THE IMPORTANCE OF FREQUENT RAPID ANTIGEN TEST SCREENING Turnaround time and frequency can be more important than sensitivity in stopping the spread of COVID-19. “ We need to change the paradigm of COVID- 19 testing and greatly expand the number of tests to be used frequently and give results back im

  9. Slide 9: Private Sector Use Cases

    Slide 9: Private Sector Use Cases

    PRIVATE SECTOR USE CASES FOCUS IS ON INDUSTRIES THAT REQUIRE PHYSICAL PRESENCE TO CREATE VALUE HIGH MINING AIRPORTS ADDITIONAL CHANNELS AIRLINES MEAT PACKING TO MARKET: RESTAURANTS LONG TERM • Occupational health THEME MANUFACTURING CARE CRUISE consultants PARKS SHIPS ECONOMIC BENEFIT OF HOTELS • Me

  10. Slide 10: Leveraging Real-Time Data

    Slide 10: Leveraging Real-Time Data

    LEVERAGING REAL-TIME DATA Sona partners with Bond Digital Health Solutions to enable real-time data management. Bond Digital Health is a leading provider of digital solutions for LFAs. Built in partnership with Bond, the Sona Connect app offers an end-to-end digital platform that enhances lateral fl

  11. Slide 11: COVID-19 Market Opportunity

    Slide 11: COVID-19 Market Opportunity

    COVID-19 MARKET OPPORTUNITY With only a handful of rapid tests approved, demand still far outweighs production capacity. DAILY COVID-19 TESTS PER THOUSAND PEOPLE (Rolling 7-day average) “ There is a near infinite demand for COVID-19 tests, and we need screening testing capabilities 100 times greater

  12. Slide 12: Potential Near-Term Drivers

    Slide 12: Potential Near-Term Drivers

    POTENTIAL NEAR-TERM DRIVERS Sona’s COVID-19 antigen test is being reviewed by Health Canada and Saudi FDA for approvals to manufacture and distribute. SONA’s in-field and third-party lab testing results supported the applications to regulators for approval in late August 2020 with approvals pending.

  13. Slide 13: Second Commercialization: Concussion Screening Test

    Slide 13: Second Commercialization: Concussion Screening Test

    SECOND COMMERCIALIZATION: CONCUSSION SCREENING TEST Sona is applying its GNR technology to develop a rapid concussion screening test. The test will detect the presence of GFAP (glial fibrillary acidic protein), a biological marker associated with concussions, typically released into the blood stream

  14. Slide 14: Opportunity to Disrupt Diagnostics

    Slide 14: Opportunity to Disrupt Diagnostics

    OPPORTUNITY TO DISRUPT DIAGNOSTICS Sona’s high sensitivity gold nanorod technology has multiple diagnostic ‘in-vitro’ applications well beyond COVID-19, all with >1B TESTS PRODUCED opportunity to gain market share from multi-billion-dollar verticals IN 2017 3 Bacterial and fungal tests to Infectious

  15. Slide 15: Longer Term Applications

    Slide 15: Longer Term Applications

    LONGER TERM APPLICATIONS Because they are non-toxic, Sona's gold nanorods can be used in ‘in-vivo’ applications in which they are used for tracking and targeting with the potential for profound implications. IN-VITRO IN-VIVO Diagnostics / Detection Drug Delivery Photothermal Therapy Cell Imaging Use

  16. Slide 16: Why Invest in Sona Nanotech?

    Slide 16: Why Invest in Sona Nanotech?

    WHY INVEST IN SONA NANOTECH? Patent pending GNR platform technology without CTAB positions Sona to disrupt the $25B global diagnostic market Aligned with industry leading partners to commercialize, manufacture and deliver millions of COVID-19 tests after approval from health regulators is received P

  17. Slide 17: Investor Highlights

    Slide 17: Investor Highlights

    INVESTOR HIGHLIGHTS CSE:SONA | OTC:SNANF approvals. MARKET CAPITALIZATION Shares Outstanding 61M Insider Ownership 13.4% Market Cap $208M CDN 52 Week High $16.05 Previous Quarter 635,858 Average Daily Volume * As of November 6, 2020 RESEARCH COVERAGE Maxim Group | Jason McCarthy, Ph.D. SONANANO. CSE

  18. Slide 18: Management & Scientific Advisors

    Slide 18: Management & Scientific Advisors

    MANAGEMENT & SCIENTIFIC ADVISORS DR. KULBIR SINGH ▪ Responsible for new product development Founder & Head of R&D ▪ Named author on 35 research papers and 2 patents ▪ Business and commercial operations oversight DAVID REGAN ▪ Strategy consultant and corporate director Chief Executive Officer ▪ 15 ye

  19. Slide 19: Board of Directors

    Slide 19: Board of Directors

    BOARD OF DIRECTORS DR. MICHAEL GROSS, MBBS, ▪ Professor of Orthopaedic surgery, medical director of the Regional Tissue Bank FRCSC, ICD.D ▪ Director of Linear Gold (sold to Brigus Gold) Director ▪ Current director of Fortune Bay, Chair Boomersplus ▪ Former President of Sanofi Pasteur Limited, the Ca

  20. Slide 20: Contact

    Slide 20: Contact

    CONTACT WWW.SONANANO.COM | +1-902-209-2232 1969 Upper Water Street Suite 2001, Purdy’s Tower II Halifax, Nova Scotia, Canada B3J 3R7 DAVID REGAN KIN COMMUNICATIONS CEO Investor Relations +1-902-448-1416 +1 604-684-6730 david@sonanano.com SONA@kincommunications.com SONANANO. CSE:SONA | OTC:SNANF COM

Source: Internet Archive copy of sonanano.com

More decks from Sona Nanotech, Inc.

All 17 Sona Nanotech decks